TOBRAMYCIN
TREATMENT
OF
PSEUDOMONAS
AERUGINOSA
INFECTIONS
IN
CYSTIC
FIBROSIS
TOBRAMYCIN
TREATMENT
OF
CHRONIC
PULMONARY
INFECTIONS
CAUSED
BY
PSEUDOMONAS
AERUGINOSA
IN
13
CHILDREN
WITH
CYSTIC
FIBROSIS
WAS
EVALUATED
INITIALLY
THE
PATIENTS
RECEIVED
THE
RECOMMENDED
DOSE
OF
125
MGM224
HOURS
THE
DOSE
WAS
THEN
INCREASED
TO
250
MGM224
HOURS
APPROXIMATELY
10
MGKG24
HOURS
THIS
HIGHER
DOSAGE
WAS
ADMINISTERED
INTRAMUSCULARLY
TO
9
PATIENTS
EIGHT
OF
THESE
RECEIVED
ADDITIONAL
THERAPY
WITH
AN
AEROSOL
CONTAINING
TOBRAMYCIN
WITH
THIS
THERAPY
IT
WAS
POSSIBLE
TO
ERADICATE
PS
AERUGINOSA
FROM
THE
RESPIRATORY
TRACT
IN
5
OF
THE
PATIENTS
AFTER
DISCONTINUING
THERAPY
PS
AERUGINOSA
REOCCURRED
IN
ALL
PATIENTS
WITHIN
ONE
MONTH
ALL
PATIENTS
SHOWED
A
CLINICAL
IMPROVEMENT
IN
RELATION
TO
THERAPY
NO
TOXIC
OR
ALLERGIC
SIDE
EFFECTS
WERE
OBSERVED
